AI Tools for Health & Medicine
From drug discovery acceleration to clinical NLP and imaging analysis — the AI tools with genuine research utility in medicine, and the trust and regulatory considerations you can't skip.
Why this field requires extra care
Medical AI is one of the most hyped and most consequential areas of AI in science. Tools range from genuinely transformative (AlphaFold’s impact on drug target identification) to dangerously overconfident (LLMs hallucinating drug interactions or clinical facts). This guide focuses on tools with demonstrated research utility — not tools marketed to clinicians. The distinction matters: a tool useful for accelerating drug discovery research is a very different proposition from a tool advising on patient care.
Everything here is for research contexts. For clinical decision support, your institution’s regulatory and ethics review processes apply regardless of what any tool claims about its accuracy.
Core tools
AlphaFold (AlphaFold DB / AlphaFold3)
What it does: Predicts 3D protein structures from amino acid sequences with near-experimental accuracy. For drug discovery, this means researchers can now obtain structural models of disease-relevant protein targets — including previously “undruggable” targets with no available crystal structure — in minutes rather than years of crystallography.
Access: AlphaFold DB (all human proteome + key organisms) free at alphafold.ebi.ac.uk. AlphaFold3 via Google DeepMind server for non-commercial research.
Best for: Identifying and characterizing drug targets, understanding protein-ligand binding sites, and structure-based virtual screening for lead compounds.
Note: See the Structural Biology field guide for a deeper treatment of AlphaFold and its companion tools.
NVIDIA BioNeMo
What it does: A cloud platform providing pre-trained large language models and generative AI models for drug discovery — including models for protein structure prediction, molecular generation, and protein-ligand docking. It brings together several state-of-the-art models (ESMFold, MolMIM, DiffDock) under one API rather than requiring researchers to set up each separately.
Access: Available through NVIDIA’s cloud services; academic access programs exist. Some underlying models (ESMFold, DiffDock) are also available as standalone open-source releases.
Best for: Computational drug discovery pipelines that need multiple model types — structure prediction, molecule generation, and docking — integrated together. Most useful for groups with some computational infrastructure.
Consensus
What it does: An AI-powered search engine that retrieves peer-reviewed research and synthesizes findings across papers. Unlike general LLMs, it cites specific papers for every claim and is designed to give evidence-based answers rather than generated text.
Access: Free tier available at consensus.app; paid plans for heavier use.
Best for: Rapid evidence synthesis for clinical research questions, systematic review scoping, and checking whether a research question has already been addressed in the literature. Substantially more reliable for factual claims than general-purpose LLMs because outputs are grounded in retrieved papers.
Note: Coverage skews toward English-language PubMed-indexed research. For clinical questions requiring comprehensive coverage (formal systematic reviews, HTA work), treat this as a scoping tool rather than a replacement for a full database search.
Elicit
What it does: An AI research assistant that helps find, screen, and extract data from research papers. Particularly strong at structured data extraction — pulling specific columns of information (sample size, intervention, outcome, effect size) from multiple papers into a table.
Access: Free tier; paid plans for larger workloads. Available at elicit.com.
Best for: Screening papers for systematic reviews or meta-analyses, and extracting structured data from clinical trial reports. The table extraction feature meaningfully reduces the manual work of evidence synthesis.
NVIDIA Clara / Medical Imaging AI
What it does: A platform for developing and deploying AI models for medical imaging analysis — including tools for image segmentation, annotation, and federated learning across hospital sites without sharing raw patient data.
Access: Available through NVIDIA; primarily aimed at research institutions and hospital systems with GPU infrastructure.
Best for: Research groups developing or validating imaging AI models (radiology, pathology, ophthalmology). The federated learning component is relevant for multi-site clinical research where data cannot leave each institution.
Note: This is a development and research platform, not a clinical tool. Models built on Clara still require clinical validation and regulatory clearance before patient use.
Suggested workflow
| Step | Tool | Purpose |
|---|---|---|
| 1 | Consensus / Elicit | Scope the literature — what’s known, what’s been tried |
| 2 | AlphaFold DB | Characterize protein targets with no available crystal structure |
| 3 | BioNeMo / DiffDock | Screen candidate molecules for binding to the target |
| 4 | Chemistry tools | Plan synthesis routes for promising candidates |
| 5 | Experimental validation | Confirm computational predictions in vitro before advancing |
What these tools can’t do yet
- LLMs are not safe for clinical facts without grounding. General-purpose LLMs (ChatGPT, Claude, Gemini) can generate plausible-sounding but incorrect drug dosages, interactions, and clinical guidelines. For any clinical or pharmacological fact, verify against a primary source — never rely on an LLM’s ungrounded answer.
- Drug discovery AI accelerates the early pipeline, not the whole pipeline. The tools above help with target identification and lead generation — steps that previously took years. They do not compress clinical trials, regulatory review, or manufacturing scale-up, which still dominate drug development timelines.
- Imaging AI performance degrades across sites. Models trained on one institution’s scanner and patient population often underperform on data from a different site. Multi-site validation is essential before drawing conclusions about generalizability.
- Federated learning is not a privacy guarantee. Federated approaches reduce, but do not eliminate, privacy risk. Model gradient leakage attacks can partially reconstruct training data. Institutional review and data governance requirements still apply.
- Biomedical literature synthesis tools can miss non-English and grey literature. For health technology assessment or policy-relevant systematic reviews, AI-assisted synthesis over PubMed is a starting point, not a complete search strategy.
Regulatory and ethics notes
Research use of AI in medicine carries responsibilities beyond other fields:
- IRB/ethics review applies to studies using patient data, even if the AI tool itself is not the intervention.
- Model cards and transparency — know what data your tools were trained on and what populations may be underrepresented.
- FDA / EMA clearance is required before AI tools are used in clinical decision-making, regardless of research performance.
- Disclosure requirements for AI-assisted research are increasingly expected by journals — check target journal policies before submission.
Related content
- Glossary: “Federated learning,” “Virtual screening,” “Structure-based drug design,” “Hallucination (AI)”
- Field Guide: Structural Biology — AlphaFold and protein design in depth
- Field Guide: Chemistry — synthesis planning tools for drug candidates